MYCN and neuroblastoma: ASCT plus local radiation therapy (RT) improved outcome in a small series (n=12), [9] but ASCT did not improve event-free survival (EFS) or overall survival (OS) of either MYCN-amplified stage 2 patients (n=39) collected by the International NB Risk Group (INRG) [13] or stage 3 patients (n=72) deemed high risk (including MYCN-non-amplified disease) in a national study [14].